GLP-1 Drugs for Weight Loss: How Semaglutide and Tirzepatide Are Reshaping Medicine
Quick Facts
What Are GLP-1 Drugs and How Do They Work for Weight Loss?
Glucagon-like peptide-1 (GLP-1) receptor agonists work by mimicking GLP-1, an incretin hormone naturally released by the gut after eating. These drugs bind to GLP-1 receptors in the brain's appetite-regulating centers, particularly the hypothalamus, to promote satiety and reduce food intake. They also slow gastric emptying, which helps people feel full longer after meals. Originally developed for type 2 diabetes management, drugs like semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have demonstrated substantial weight loss in clinical trials.
In the landmark STEP trials, semaglutide 2.4 mg weekly produced average weight reductions of approximately 15% of body weight over 68 weeks. Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed even greater efficacy in the SURMOUNT program, with participants losing up to 22% of body weight at the highest dose. These results have fundamentally changed the treatment landscape for obesity, which the American Medical Association recognized as a chronic disease in 2013. The FDA approved semaglutide for chronic weight management in 2021 and tirzepatide for the same indication in 2023.
What Health Benefits Do GLP-1 Drugs Offer Beyond Weight Loss?
The SELECT trial, published in The New England Journal of Medicine in 2023, demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in people with overweight or obesity and established cardiovascular disease — crucially, this benefit was observed regardless of diabetes status. This led the FDA to approve semaglutide as the first weight loss medication with an indication for cardiovascular risk reduction. Additionally, the FLOW trial showed that semaglutide slowed the progression of chronic kidney disease in patients with type 2 diabetes, reducing the risk of kidney failure events by approximately 24%.
Researchers are now investigating GLP-1 drugs for metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH), with semaglutide showing histological improvement in liver inflammation in phase 2 trials. Tirzepatide has also demonstrated efficacy in treating moderate-to-severe obstructive sleep apnea in the SURMOUNT-OSA trial. These expanding indications suggest that the metabolic improvements driven by GLP-1 drugs extend well beyond glucose control and appetite suppression, addressing the systemic inflammatory and metabolic processes underlying multiple chronic conditions.
What Are the Side Effects and Risks of GLP-1 Weight Loss Medications?
Gastrointestinal side effects are the most frequently reported adverse events with GLP-1 receptor agonists. In clinical trials, nausea affected roughly 40–45% of participants on semaglutide and tirzepatide, though it was most prominent during dose escalation and tended to decrease over subsequent weeks. Vomiting, diarrhea, and constipation are also common. These effects are directly related to the drugs' mechanism of slowing gastric emptying. Gradual dose titration over several weeks is the standard approach to minimize these symptoms, and most patients who tolerate the escalation period report significant improvement.
More serious but rarer concerns include pancreatitis, gallbladder disease, and a theoretical risk of medullary thyroid carcinoma based on preclinical animal studies — though this has not been confirmed in human data. Healthcare providers also monitor for potential worsening of diabetic retinopathy with rapid glucose improvements. Another key consideration is weight regain after discontinuation: the STEP 1 extension trial showed that participants regained approximately two-thirds of lost weight within one year of stopping semaglutide, underscoring that obesity treatment with these drugs may need to be long-term. Supply shortages have also been a significant issue, with the FDA listing semaglutide on its drug shortage database through much of 2023 and 2024.
Frequently Asked Questions
Current evidence suggests GLP-1 medications for weight loss may need to be taken long-term to maintain results. Clinical trial data show that most patients regain a significant portion of weight within a year of stopping treatment, similar to the pattern seen with other chronic disease medications like blood pressure drugs.
Yes, semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved specifically for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition, regardless of diabetes status. The SELECT trial confirmed cardiovascular safety and benefit in non-diabetic populations.
Without insurance, brand-name GLP-1 medications can cost over $1,000 per month in the United States. Insurance coverage varies widely, with many plans covering these drugs for diabetes but not for weight management. The cost barrier remains one of the most significant challenges to equitable access.
While GLP-1 drugs produce significant weight loss, bariatric surgery generally achieves greater and more durable results, with average weight loss of 25–35% of body weight. The choice depends on individual factors including BMI, comorbidities, and patient preference. Some patients may benefit from combining both approaches.
References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management. 2021.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.